Publication at Second Faculty of Medicine |
2012
Abstract
Vitiligo represents a selective destruction of the melanocytes. It is a relatively common, probably autoimmune disorder that affects people of all backgrounds and both genders.
No particular group seems to be preferentially affected. Half of vitiligo patients have an onset before the age of 18 years.
In regions where leprosy is endemic, individuals with vitiligo are often stigmatized due to similarities in appearance between the two diseases. We will review this important subject, emphasizing the latest therapeutic advances.